Cristina Marinescu, Ana-Maria Vladareanu and Felicia Mihai
, LAZARUS HM, FRANKLIN IM, LITZOW MR, CIOBANU N, PRENTICE HG, DURRANT J, TALLMAN MS & GOLDSTONE AH. Induction therapy for adults with acutelymphoblasticleukaemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106, 3760-3767.
5. JACOB M ROWE. Prognostic factors in adult acutelymphoblasticleukaemia. British Journal of Haematology, 2010, 150, 389-405.
6. MOORMAN AV, CHILTON L, WILKINSON J, et al. A population-based cytogenetic study of adults with acutelymphoblasticleukemia
review of literature. J Hematol Oncol. 2009; 2(1): 26-31.
3. Atlas of Genetics and Cytogenetics in Oncology and Haematology online, 1998 (http://atlasgeneticsoncol ogy.org/).
4. Bargetzi MJ, Mühlematter D, Tichelli A, Jotterand M, Wernli M. Dicentric translocation (9;12) presenting as refractory Philadelphia chromosomepositive acute B-cell lymphoblastic leukemia. Cancer Genet Cytogenet. 1999; 113(1): 90-92.
5. D’Angelo G, Hotz AM, Todeschin P. Acutelymphoblasticleukemia with hypereosinophilia and 9p21 deletion: case
Hasan A. Burnusuzov, Mariya I. Spasova, Mariana A. Murdjeva, Angelina A. Stoyanova, Ivan N. Mumdziev, Valeriya I. Kaleva, Milena I. Belcheva and Miroslava N. Bosheva
1. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acutelymphoblasticleukaemia and its relationship to other prognostic factors: A Children’s Oncology Group study. Blood 2008;111:5477-85.
2. Campana D. Minimal residual disease monitoring in childhood acutelymphoblasticleukemia. Curr Opin Hematol 2012;19(4):313-8.
3. Bartram CR, Schrauder A, Köhler R, Schrappe M. Acutelymphoblasticleukemia in children. Treatment planning via minimal
Rina Mutiara, Bernadius Agustinus, Christian Badia Sitompul, Amarila Malik, Djajadiman Gatot and Frans D. Suyatna
[ 2 ]. The most common malignancy in the pediatric population worldwide is acutelymphoblasticleukemia (ALL). ALL is a heterogeneous group of leukemias that result from the clonal proliferation of cancerous lymphoblasts in bone marrow, and in secondary lymphoid organs. Children 1–10 years old are at particular risk of developing ALL. The overall cure rate is approximately 80% [ 3 ].
The Indonesian Paediatric Oncology Foundation stated that 2%-3% cancer cases in Indonesia occur in children [ 4 ]. Based on Cipto Mangunkusumo Hospital data from 2000-2006, there were
acutelymphoblasticleukemia in Northern Ireland. Community Dent Oral Epidemiol. 1993;21(5):309-12.
17. Kinirons MJ, Fleming P, Boyd D. Dental caries experience of children in remission from acutelymphoblasticleukaemia in relation to the duration of treatment and the period of time in remission. Int J Paediatr Dent. 1995;5(3):169-72.
18. Sonis AL, Waber DP, Sallan S, Tarbell NJ. The oral health of long-term survivors of acute lymphoblastic lekaemia: a comparisonof three treatment modalites. Oral Oncol Eur J Cancer. 1995;31B(4):250-2.
19. Avşar A, Elli M, Darka
Morgan Covington, Juliana Gao, Farah Abdulla and Vesna Petronić Rosić
Fusarium is a ubiquitous fungal species found in soil and water. While fusarium can cause localized infection in healthy individuals, it most commonly affects those with compromised immune systems, particularly those with prolonged neutropenia. The morality rate of systemic infection approaches one-hundred percent. Here we present two cases of disseminated fusarium infection in two patients with acute lymphoblastic leukemia (ALL) along with review of literatures regarding prophylaxis and treatment.
Vladimir Gasic, Branka Zukic, Biljana Stankovic, Dragana Janic, Lidija Dokmanovic, Jelena Lazic, Nada Krstovski, Vita Dolzan, Janez Jazbec, Sonja Pavlovic and Nikola Kotur
Acutelymphoblasticleukemia (ALL) is the most common hematological and overall malignancy in pediatrics, accounting for around 30% of all childhood cancers and around 80% of all childhood leukemias. It is one of the pediatric malignancies with the highest cure rate, exceeding 80%, when treated with standardized protocols like the European standard, the Berlin-Frankfurt-Munster (BFM) protocol. 1 , 2 , 3 However, there is still more than 10% of patients with unfavorable outcome. The treatment of childhood ALL is based on risk stratification
Vladimir Gasic, Biljana Stankovic, Branka Zukic, Dragana Janic, Lidija Dokmanovic, Nada Krstovski, Jelena Lazic, Goran Milosevic, Marianna Lucafò, Gabriele Stocco, Giuliana Decorti, Sonja Pavlovic and Nikola Kotur
Among pediatric malignancies, acutelymphoblasticleukemia (ALL) is the most common hematological and overall malignancy, contributing to 30% of diagnosed cancers and around 80% of all pediatric leukemias. Pediatric ALL is a malignancy with one of the highest cure rates, achieved by treating the patients with the internationally recognised treatment protocols like the Berlin-Frankfurt-Munster (BFM) protocol ( 1 , 2 , 3 ). Risk stratification of ALL is para mount in choosing the effective treatment strategy. Hence, risk stratification is already